Our findings suggest that targeting SLC7A11 through engineered BEVs presents a promising approach to inhibit NSCLC progression while activating ferroptosis, offering insights into novel therapeutic strategies against lung cancer. The gene discussed is SLC7A11; the disease is non-small cell lung carcinoma.